More than 75% of the 3 billion base pairs in our genome are transcribed into RNA, yet only 1-2% are translated into proteins. Our lab investigates this RNA “dark matter” of unknown function in the context of stem cells and cancer. We use genomic and genome engineering technologies to discover and understand the functions of these noncoding RNAs. In particular, our lab investigates how RAS signaling regulates the noncoding transcriptome during cancer initiation and in pluripotent stem cells. We are leveraging these discoveries to develop RNA-based liquid biopsy approaches to enable highly sensitive and specific early detection of RAS-driven cancers and other diseases using genomic approaches.